|Karolinska Development AB -- Sweden Stock|| |
SEK 5.16 0.04 0.77%
Vice President - Operations
Dr. Gunilla Ekstrom was Vice President Operations at Karolinska Development AB since June 2012. Gunilla Ekstrom has over 20 years of experience from senior positions in the pharmaceutical industry including as Senior Vice President at Orexo AB and Global Product Director at AstraZeneca RD. She is also Board member of Athera Biotechnologies AB Biosergen AS Inhalation Sciences Sweden AB Lipidor AB NovaSAID AB Pharmanest AB and CEO of Biosergen AS. She holds Doctorate of Medicine and Doctorate in Philosophy degrees and is Associate Professor at Karolinska Institutet.
Age: 54 President Since 2012 Ph.D
46 8 52 48 60 70 http://www.karolinskadevelopment.com
The company has return on total asset (ROA)
of (3.86) %
which means that it has lost $3.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of 120.96 %
meaning that it generated $120.96 on every $100 dollars invested by stockholders.
The company has accumulated 379.18 M in total debt with debt to equity ratio (D/E) of 141.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 13.84 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 13 people.